over 3m buyer, page-20

Company with related technology to Prima Biomed:

Dendreon Corp. (DNDN, $6.17, +$1.07, +20.98%) has been one of the worst-performing biotech stocks over the last two years amid reimbursement issues for its Provenge prostate cancer drug, but Bernstein said Friday that interviews with the drug's "busiest prescribers" showed they are not only increasing their use but recruiting others to use the product as well. With that, Bernstein forecasted "slow but steady revenue growth" for Dendreon and said it sees signs the "progressive disaster" at the company could be coming to an end. The firm raised its price target by 43% to $10 a share and upgraded the stock to an outperform rating.